









市場行情
/
股票
/
nasdaq-wve
/

WAVE Life Sciences Ltd

WVE

17.000USD

-0.150-0.87%

收盤 12/31, 16:00（美東）報價延遲15分鐘

2.72B總市值

虧損本益比TTM



WAVE Life Sciences Ltd

17.000

-0.150-0.87%

概覽公司財務分析

概覽

公司

財務

分析

關於 WAVE Life Sciences Ltd 公司

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).

WAVE Life Sciences Ltd簡介



公司代碼WVE

公司名稱WAVE Life Sciences Ltd

上市日期Nov 11, 2015

CEOBolno (Paul B)

員工數量287

證券類型Ordinary Share

年結日Nov 11

公司地址7 Straits View

城市

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Singapore

郵編018936

電話6562363388

網址https://www.wavelifesciences.com/

公司代碼WVE

上市日期Nov 11, 2015

CEOBolno (Paul B)

WAVE Life Sciences Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Chandra Vargeese, Ph.D.

Chief Technology Officer, Head - Platform Discovery Sciences

302.31K

Mr. Kyle Moran

Chief Financial Officer

60.96K

+143.86%

Ms. Heidi L. Wagner, J.D.

Independent Director

28.82K

Ms. Aik Na Tan

Independent Director

25.40K

-37.11%

Mr. Ken Takanashi

Independent Director

23.94K

+48.58%

Mr. Christian O. Henry

Independent Chairman of the Board

12.70K

-33.66%

Dr. Paul B. Bolno, M.D.

President, Chief Executive Officer, Director

Dr. Christopher John Francis, Ph.D.

Senior Vice President - Corporate Development, Head - Emerging Areas

Dr. Gregory L. (Greg) Verdine, Ph.D.

Director

Dr. Peter Kolchinsky, Ph.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Chandra Vargeese, Ph.D.

Chief Technology Officer, Head - Platform Discovery Sciences

302.31K

Mr. Kyle Moran

Chief Financial Officer

60.96K

+143.86%

Ms. Heidi L. Wagner, J.D.

Independent Director

28.82K

Ms. Aik Na Tan

Independent Director

25.40K

-37.11%

Mr. Ken Takanashi

Independent Director

23.94K

+48.58%

Mr. Christian O. Henry

Independent Chairman of the Board

12.70K

-33.66%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月15日週六

持股股東

股東類型

持股股東

佔比

GSK plc

9.98%

RA Capital Management, LP

9.97%

Adage Capital Management, L.P.

7.97%

BlackRock Institutional Trust Company, N.A.

4.78%

Maverick Capital, Ltd.

4.59%

其他

62.71%

持股股東

佔比

GSK plc

9.98%

RA Capital Management, LP

9.97%

Adage Capital Management, L.P.

7.97%

BlackRock Institutional Trust Company, N.A.

4.78%

Maverick Capital, Ltd.

4.59%

其他

62.71%

股東類型

持股股東

佔比

Investment Advisor

29.00%

Hedge Fund

21.22%

Investment Advisor/Hedge Fund

16.23%

Corporation

14.13%

Venture Capital

10.06%

Research Firm

1.89%

Individual Investor

0.41%

Bank and Trust

0.23%

Pension Fund

0.21%

其他

6.61%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

368

140.86M

88.47%

+5.01M

2025Q2

364

156.69M

98.46%

-1.61M

2025Q1

368

156.82M

101.38%

+1.16M

2024Q4

342

152.89M

100.27%

+6.14M

2024Q3

306

144.44M

97.59%

+25.71M

2024Q2

274

116.00M

94.13%

+429.46K

2024Q1

255

115.83M

95.69%

+2.66M

2023Q4

240

115.18M

98.42%

+19.70M

2023Q3

224

93.79M

97.86%

+5.83M

2023Q2

224

93.41M

97.80%

+7.66M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

GSK plc

16.78M

10.54%

Jun 06, 2025

RA Capital Management, LP

18.21M

11.44%

+12.70K

+0.07%

Aug 11, 2025

Adage Capital Management, L.P.

15.02M

9.43%

+2.50M

+19.97%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.75M

5.5%

+540.89K

+6.59%

Jun 30, 2025

Maverick Capital, Ltd.

8.26M

5.19%

Jun 30, 2025

Driehaus Capital Management, LLC

6.53M

4.1%

+172.92K

+2.72%

Jun 30, 2025

Shin Nippon Biomedical Laboratories Ltd

5.71M

3.58%

Jun 06, 2025

M28 Capital Management LP

5.66M

3.56%

Jun 30, 2025

Emerald Advisers LLC

5.19M

3.26%

+130.23K

+2.57%

Jun 30, 2025

Kynam Capital Management LP

4.56M

2.86%

-339.44K

-6.93%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

State Street SPDR S&P Pharmaceuticals ETF

1.81%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.34%

Global X Genomics & Biotechnology ETF

1.25%

Virtus LifeSci Biotech Clinical Trials ETF

0.85%

iShares U.S. Pharmaceuticals ETF

0.41%

First Trust Multi-Manager Small Cap Opportunities ETF

0.26%

iShares Micro-Cap ETF

0.19%

Franklin Genomic Advancements ETF

0.19%

ProShares Ultra Nasdaq Biotechnology

0.15%

Invesco Nasdaq Biotechnology ETF

0.14%

State Street SPDR S&P Pharmaceuticals ETF

佔比1.81%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.34%

Global X Genomics & Biotechnology ETF

佔比1.25%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.85%

iShares U.S. Pharmaceuticals ETF

佔比0.41%

First Trust Multi-Manager Small Cap Opportunities ETF

佔比0.26%

iShares Micro-Cap ETF

佔比0.19%

Franklin Genomic Advancements ETF

佔比0.19%

ProShares Ultra Nasdaq Biotechnology

佔比0.15%

Invesco Nasdaq Biotechnology ETF

佔比0.14%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

WAVE Life Sciences Ltd的前五大股東是誰？



WAVE Life Sciences Ltd的前五大股東如下：
GSK plc
持有股份：16.78M
佔總股份比例：10.54%。
RA Capital Management, LP
持有股份：18.21M
佔總股份比例：11.44%。
Adage Capital Management, L.P.
持有股份：15.02M
佔總股份比例：9.43%。
BlackRock Institutional Trust Company, N.A.
持有股份：8.75M
佔總股份比例：5.50%。
Maverick Capital, Ltd.
持有股份：8.26M
佔總股份比例：5.19%。